$22.05
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
Overview
52-week range
$8.59
$26
79% of range
Avg surprise (last 2)
+11.4%
Avg reaction (last 1)
-1.2%
0% positive
Latest IV / EM
77%
EM ±17.7% · $22 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.48 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.70 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $-0.83 | $1.00 | +17.0% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.98 | $-1.04 | +5.8% | — | -1.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.98 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.80 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.85 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.64 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 3, 2026 | Jun/2026 | OTHER | -$0.45 | -$0.83 | +45.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65M | — | $46M | $38M | $20M | — | $12M | $4M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-34M | — | $-57M | $-69M | $-84M | — | $-90M | $-74M |
| Net income | $-43M | — | $-61M | $-72M | $-85M | — | $-84M | $-68M |
| EPS (diluted) | $-0.48 | — | $-0.70 | $-0.83 | $-0.98 | — | $-0.98 | $-0.80 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $131M | $135M | $117M | $109M | $154M | $154M | $133M | $105M |
| Inventory | $35M | $33M | $25M | $18M | $5M | $366,000 | — | — |
| Total current assets | $471M | $528M | $530M | $532M | $549M | $603M | $415M | $446M |
| Total assets | $473M | $530M | $552M | $596M | $641M | $725M | $426M | $477M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $431M | $465M | $436M | $439M | $426M | $437M | $59M | $43M |
| Total equity | $42M | $65M | $115M | $157M | $215M | $288M | $366M | $434M |